Table 2

Optimization of the GBVA peptide sequence and antiviral activity

No.NameSequenceaLength (aab)DescriptionIC50 (μM)% inhibition at 20 μM
10GBVA1LLDCWVRLGRYLLRRLKT18aa 1–181088
11GBVA2LLDCWVRLGRYLLRRLKTPFTRL23aa 1–231550
12GBVA3LLDCWVRLGRYLLRRLKTPFT21aa 1–21>200
13GBVA4LLDCWVRLGRYLLRRLKTP19aa 1–19399
14GBVA5LLDCWVRLGRYLLRRLK17aa 1–17599
15GBVA6LDCWVRLGRYLLRRLKTPFTRL22aa 2–23>200
16GBVA7CWVRLGRYLLRRLKTPFTRL20aa 4–231289
17GBVA8LDCWVRLGRYLLRRLKTP18aa 2–19499
18GBVA9DCWVRLGRYLLRRLKTPF18aa 3–201290
19GBVA10CWVRLGRYLLRRLKTPFT18aa 4–212100
20GBVA11WVRLGRYLLRRLKTPFTR18aa 5–221258
21GBVA12VRLGRYLLRRLKTPFTRL18aa 6–23>200
  • a The underlining in the first sequence indicates interchanged amino acids.

  • b aa, amino acids.